Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ctDNA for recurrence detection in high-risk resected melanoma

Observational study using serial ctDNA to infer recurrence risk in stage III and limited stage IV melanoma. ClinicalTrials.gov lists the study as completed.

Case Comprehensive Cancer Center